HealthDay News – The vaccine effectiveness of two doses of Moderna mRNA-1273 is 87.4 percent against COVID-19 infection and 95.8 and 97.9 percent, respectively, against COVID-19 hospital admissions and death, according to an online November 25 in The Lancet. published study Regional Health: America.
Katia J. Bruxvoort, Ph.D., MPH, of Kaiser Permanente Southern California in Pasadena, and colleagues performed a scheduled interim analysis of 352,878 subjects aged 18 years who received two doses of mRNA-1273 24 days apart . December). 2020, until March 31, 2021) compared with 352,878 randomly selected unvaccinated people with follow-up until June 30, 2021. The results were COVID-19 infection or serious illness.
The researchers found that the vaccine’s effectiveness was 87.4, 95.8, and 97.9 percent, respectively, against COVID-19 infection, COVID-19 hospitalization, and COVID-19 hospital death, respectively. The vaccine effectiveness was higher in symptomatic COVID-19 than in asymptomatic COVID-19 (88.3 versus 72.7 percent) and was generally similar across subgroups based on age, gender, and race / ethnicity. In people with a history of COVID-19 infection, vaccine effectiveness ranged from 8.2 to 33.6 percent. The most common coronavirus-2 variants of severe acute respiratory syndrome were alpha, epsilon, delta, and gamma (41.6, 17.5, 11.5 and 9.1 percent, respectively); By June 2021, the delta had increased to 54.0 percent of the variants.
Continue reading
“This study provides evidence of the effectiveness of the Moderna COVID-19 vaccine in the real world, particularly in the general population,” a co-author said in a statement. “Our follow-up visits to these fully vaccinated patients were through June 2021, a period that coincided with the arrival of the Delta variant in the United States.”
Several authors disclosed financial ties to pharmaceutical companies, including Moderna, which makes the mRNA 1273 vaccine and is funding the study.
Summary / full text
